Биохимические маркеры метастазирования в кости
https://doi.org/10.17650/2313-805X.2015.2.1.061-075
Аннотация
Об авторах
Нина Васильевна ЛюбимоваРоссия
Россия, 115478, Москва, Каширское шоссе, 24
Н. Е. Кушлинский
Россия
Россия, 115478, Москва, Каширское шоссе, 24
Список литературы
1. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. Под ред. М.И. Давыдова, Е.М. Аксель. М.: Издательская группа РОНЦ, 2014. 226 с. [Statistics of malignant tumours in Russia and CIS countries in 2012. under the editorship of M.I. Davydova, E.M. Aksel. Moscow: Publishing Group of Russian Cancer Research Center, 2014. Pp. 226. (In Russ.)].
2. Любимова Н.В., Кушлинский Н.Е. Маркеры костного ремоделирования: общие представления и клиническое значение при поражении скелета у онкологических больных. Вопросы онкологии 2001;47(1):18–23. [Lyubimova N.V., Kushlinsky N.E. Bone turnover markers: fundamental understanding and clinical relevance at skeletal lesion in oncologic patients. Voprosy onkologii = Problems in Oncology 2001;47(1):18–23. (In Russ.)].
3. Кушлинский Н.Е., Тимофеев Ю.С. Роль системы RANK/RANKL/OPG в патогенезе первичных и метастатических опухолей костей. Патогенез 2013;11(4):9–15. [Kushlinsky N.E., Timofeev Y.S. Role of RANK/RANKL/OPG system in pathogenesis of primary and metastatic bone tumours. Patogenez = Pathogenesis 2013;11(4):9–15. (In Russ.)].
4. Кушлинский Н.Е., Тимофеев Ю.С., Герштейн Е.С., Соловьев Ю.Н. Клинические перспективы исследования компонентов системы RANK/RANKL/OPG при первичных и метастатических опухолях костей. Вопросы онкологии 2014;60(4):413–21. [Kushlinsky N.E., Timofeev Y.S., Gershteyn E.S., Solovyev Y.N. Clinical prospects of system RANK/RANKL/OPG components research at primary and metastatic bone tumours. Voprosy onkologii = Problems in Oncology 2014;60(4):413–21. (In Russ.)].
5. Lee J.A., Jung J.S., Kim D.H. et al. RANKL expression is related to treatment outcome of patients with localized, highgrade osteosarcoma. Pediatr Blood Cancer 2011;56(5):738–43.
6. Roodman D. Mechanisms of bone metastasis. N Engl J Med 2004;350(16):1655–64.
7. Chu G.C., Chung L.W. RANK-mediated signaling network and cancer metastasis. Cancer Metastasis Rev 2014;33(2–3): 497–509.
8. Schramek D., Leibbrandt A., Sigl V. et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010;468(7320):98–102.
9. Martin T. J. Historically significant events in the discovery of RANK/RANKL/OPG. World J Orthop 2013;4(4):186–97.
10. Morony S., Capparelli C., Sarosi I. et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001;61(11):4432–6.
11. Choi H.K., Kang H.R., Jung E. et al. Early estrogen-induced gene 1, a novel RANK signaling component, is essential for osteoclastogenesis. Cell Res 2013;23(4): 524–36.
12. Rucci N., Millimaggi D., Mari M. et al. Receptor activator of NF-kappaB ligand enhances breast cancerinduced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147. Cancer Res 2010;70(15):6150–60.
13. Coleman R.E., Major P., Lipton A. et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23(22):4925–35.
14. Body J. J., Greipp P., Coleman R.E. et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003;97(3 Suppl):887–92.
15. ClinicalTrials.gov. Bethesda (MD): NIH. Single ascending-dose study to characterize the safety, pharmacokinetics, and pharmacodynamics of CEP-37251 in healthy postmenopausal women. 2010. Available from: http://clinicaltrials.gov/show/NCT01159873.
16. Riggs B.L., Khosla S., Atkinson E. J. et al. Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. Osteoporos Int 2003;14(9):728–33.
17. Fizazi K., Lipton A., Mariette X. et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27(10):1564–71.
18. Кушлинский Н.Е., Тимофеев Ю.С., Соловьев Ю.Н. и др. Компоненты системы RANK/RANKL/OPG, ИЛ-6, ИЛ-8, ИЛ-16, ММП-2 и кальцитонин в сыворотке крови больных с новообразованиями костей. Бюллетень экспериментальной биологии и медицины 2014;157(4):522–6. [Kushlinsky N.E., Timofeev Y.S., Solovyev Y.N. et al. Components of system RANK/RANKL/OPG, IL-6, IL-8, IL-16, MMP-2 and calcitonin in blood serum of bone tumors patients. Bulleten, eksperimental, noy biologii i meditsiny = Bulletin of Experimental Biology and Medicine 2014;157(4):522–6. (In Russ.)].
19. Wozney J.M. Overview of bone morphogenetic proteins. Spine (Phila Pa 1976). 2002;27(16 Suppl 1):2–8.
20. Hofbauer L.C., Rachner T., Singh S.K. Fatal attraction: why breast cancer cells home to bone. Breast Cancer Res 2008;10(1):101.
21. Roodman D. Biology of osteoclast activation in cancer. J Clin Oncol 2001;19(15):3562–71.
22. Sezer O., Heider U., Zavrski I. et al. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003;101(6):2094–8.
23. Pearse R.N., Sordillo E.M., Yaccoby S. et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to stimulate bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001;98(20):11581–6.
24. Choi S. J., Cruz J.C., Craig F. et al. Macrophage inflammatory protein 1–alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96(2):671–5.
25. Min H., Morony S., Sarosi I. et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000;192(4):463–74.
26. Choi S. J., Oba Y., Gazitt Y. et al. Antisense inhibition of macrophage inflammatory protein 1–alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001;108(12):1833–41.
27. Tian E., Zhan F., Walker R. et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349(26): 2483–94.
28. Fujita К., Janz S. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer 2007;6:71.
29. Hameed A., Brady J. J., Dowling P. et al. Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis 2014;7:33–42.
30. Li X., Liu Y., Wu B. et al. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis. Oncol Rep 2014;32(6):2605–11.
31. Yamabuki T., Takano A., Hayama S. et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 2007;67(6):2517–25.
32. Mundy G.R., Boyce B.F., Yoneda T. Mechanisms of osteolytic bone destruction. In: Metastatic Bone Disease: Fundamental and Clinical Aspects. Berlin, Heidelberg: Springer Verlag, 1994. Pp. 86–92.
33. Ratcliffe W.A., Bowden S. J. Parathyroid hormone-related protein: Assay and their clinical applications. In.: Calcium Regulating Hormones and Markers of Bone Metabolism: Measurement and Interpretation. Heidelberg: Clin.Lab. Publications, 1997. Pp. 71–8. Моисеенко В.М., Семиглазов В.Ф., Тюляндин С.А. Современное лекарственное лечение местнораспространенного и метастатического рака молочной железы. СПб.: Грифон, 1997. 248 c. [Moiseenko V.M., Semiglazov V.F., Tyulyandin S.A. Modern medical therapy of locally advanced and metastatic breast cancer. St. Petersburg: Grifon, 1997. 248 p. (In Russ.)].
34. Moss D.W. Diagnostic aspects of alkaline phosphatase and its isoenzymes. Clin Biochem 1987;20(4):225–30.
35. Kress B.C. Bone alkaline phosphatase in normal and disease processes. In: Calcium regulating hormones and markers of bone metabolism: measurement and interpretation. Heidelberg: Clin.Lab. Publications, 1997. Pp. 171–82.
36. Van Straalen J.P., Sanders E., Prummel M.F., Sanders G.T. Bone-alkaline phosphatase as indicator of bone formation. Clin Chim Acta 1991;201(1–2):27–33.
37. Price C.P., Thompson P.W. The role of biochemical tests in the screening and monitoring of osteoporosis. Ann Clin Biochem 1995;32(Pt 3):244–60.
38. Robins S.P., Stewart P., Astbury C., Bird H.A. Measurement of the crosslinking compound, pyridinoline, in urine as an index of collagen degradation in jont diseases. Ann Rheum Dis 1986;45(12):969–73.
39. Robins S.P., Black D., Paterson C.R. et al. Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases. Eur J Clin Invest 1991;21(1):310–5.
40. Robins S.P. Measurement of pyridinium crosslinks by HPLC and immunoassay. In: Calcium regulating hormones and markers of bone metabolism: measurement and interpretation. Heidelberg: Clin.Lab. Publications, 1997. Pp. 135–40.
41. Becker S., Traber L., Schmidt-Gayk H. Free and peptide-bound pyridinium crosslinks in urine measured in healthy people, women after menopause and patients with bone metastases. In: Calcium regulating hormones and markers of bone metabolism: measurement and interpretation. Heidelberg: Clin.Lab. Publications, 1997. Pp. 141–6.
42. Delmas P.D. Biochemical markers of bone turnover. Acta Orthop Scand Suppl 1995;266:176–82.
43. Bonde M., Qvist P., Fledelius C. et al. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): Follow-up on hormone re-placement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995;80(3):864–8.
44. Hanson D.A., Weis M.A., Bollen A.M. et al. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7(11):1251–8.
45. Рожинская Л.Я. Остеопороз: диагностика нарушений метаболизма костной ткани и кальций-фосфорного обмена. Клиническая и лабораторная диагностика 1998;(5):25–32. [Rozhinskaya L.Y. Osteoporosis: diagnostics of bone tissue metabolism and calcium-phosphoric metabolism disturbances. Klinicheskaya i laboratornaya diagnostika = Clinical and Laboratory Diagnostics 1998;(5):25–32. (In Russ.)].
46. Body J. J., Dumon J.C., Gineyts E., Delmas P.D. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis be-fore and after biphosphonate therapy. Br J Cancer 1997;75(3):408–12.
47. Любимова Н.В., Кушлинский Н.Е., Робинс С.П. Маркеры резорбции костной ткани при метастатическом поражении скелета. Бюллетень экспериментальной биологии и медицины 1998;(3):323–8. [Lyubimova N.V., Kushlinsky N.E., Robins S.P. Bone resorption markers at metastatic bone disease. Bulleten, eksperimental, noy biologii i meditsiny = Bulletin of Experimental Biology and Medicine 1998;(3):323–8. (In Russ.)].
48. Любимова Н.В., Никитина О.Ю., Робинс С.П., Кушлинский Н.Е. Биохимические маркеры костного ремоделирования у онкологических больных с поражением скелета. Вопросы онкологии 2000;(5):13–8. [Lyubimova N.V., Nikitina O.Y., Robins S.P., Kushlinsky N.E. Bone turnover biochemical markers in oncologic patients with skeletal lesion. Voprosy onkologii = Problems in Oncology 2000; (5):13–8. (In Russ.)].
49. Withold W., Friedrich W., Reinauer H. Comparision of biochemical markers of bone resorption in patients with metabolic and malignant bone diseases. Ann Clin Biochem 1996;33(Pt 5):421–7.
50. Lipton A., Demers L., Daniloff Y. et al. Increased urinary excretion of pyridinium cross-links in cancer patients. Clin Chem 1993;39(4):614–8.
51. Pecherstorfer M., Zimmer-Roth I., Schilling T. et al. The diagnostic value of urinary pyridinium cross-links of collagen, serum total phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 1995;80(1): 97–103.
52. Seibel M. J., Lambrinoudaki I., Zipf A. Biochemical markers of bone metabolism in metastatic bone disease. In: Metastatic bone disease: fundamental and clinical aspects. Berlin, Heidelberg: Springer Verlag, 1994. Pp. 109–26.
53. Lumachi F., Santeufemia D.A., Del Conte A. et al. Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer. Anticancer Res 2013;33(6):2593–6.
54. Addison C.L., Pond G.R., Zhao H. et al. Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. Springerplus 2014;3:577.
55. Любимова Н.В., Кожарская Г.В., Агеева Т.В. и др. Клиническое значение биохимических показателей костного ремоделирования при поражении скелета у больных раком молочной железы.Молекулярная медицина 2012;(5):25–9. [Lyubimova N.V., Kozharskaya G.V., Ageeva T.V. et al. Clinical relevance of bone turnover biochemical indices at skeletal lesion in breast cancer patients. Molekulyarnaya meditsina = Molecular Medecine 2012;(5):25–9. (In Russ.)].
56. Kylmälä T., Tammela T.L., Risteli L. et al. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 1995;71(5):1061–4.
57. Brown J.E., Cook R. J., Major P. et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer and other solid tumors. J Natl Cancer Inst 2005;97(1):59–69.
58. Ali S.M., Demers L.M., Leitzel K. et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with boneonly metastasis. Ann Oncol 2004;15(3):455–9.
59. Семенов Н.Н., Любимова Н.В., Кушлинский Н.Е., Личиницер М.Р. С-концевой телопептид коллагена I типа в моче – фактор прогноза при метастатическом поражении скелета у больных раком молочной железы. Технологии живых систем 2012;9(3):3–7. [Semenov N.N., Lyubimova N.V., Kushlinsky N.E., Lichinitser M.R. Beta-cross laps in urine as forecast factor at metastatic skeletal lesion in breast cancer patients. Tekhnologii zhivykh system = Living Systems Technologies 2012;9(3):3–7. (In Russ.)].
60. Berruti A., Piovesan A., Torta M. et al. Biochemical evaluation of bone turnover in cancer patients with bone metastases. Br J Cancer 1996;73(12):1581–7.
61. Du W.X., Duan S.F., Chen J. J. et al. Serum bone-specific alkaline phosphatase as a biomarker for osseous metastases in patients with malignant carcinomas: a systematic review and meta-analysis. J Cancer Res Ther 2014;10(Suppl 2):140–3.
62. Demers L.M., Costa L., Chinchilli V.M. et al. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995;41(10):1489–94.
63. Li F., Pitt P.I., Sherwood R. et al. Biochemical markers of bone turnover in women with surgically treated carcinoma of the breast. Eur J Clin Invest 1993;23(9):566–71.
64. Tang C., Liu Y., Qin H. et al. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients. Clin Chim Acta 2013;426:102–7.
65. Jung K., Lein M. Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis. Biochim Biophys Acta 2014;1846(2):425–38.
Рецензия
Для цитирования:
Любимова Н.В., Кушлинский Н.Е. Биохимические маркеры метастазирования в кости. Успехи молекулярной онкологии. 2015;2(1):061-075. https://doi.org/10.17650/2313-805X.2015.2.1.061-075
For citation:
Lyubimova N.V., Kushlinskiy N.E. Biochemical markers of bone metastasis. Advances in Molecular Oncology. 2015;2(1):061-075. (In Russ.) https://doi.org/10.17650/2313-805X.2015.2.1.061-075